All analyses
5 min read

Last updated:

Melatonin: seven minutes faster to sleep, and a labeling problem

The reference meta-analysis covers 19 trials and 1,683 participants. The gain in sleep onset is 7 minutes, the gain in total sleep time 8 minutes. These are real, small effects, set against another number: across 31 supplements analyzed, content ranged from 83 percent less to 478 percent more than the label.

7 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Bedroom in dim light, conditions for restorative sleep
Bedroom in dim light, conditions for restorative sleep

The effect exists, and it is measured in minutes

The meta-analysis published in PLoS One in 2013 pooled 19 placebo-controlled trials and 1,683 participants with primary sleep disorders. Sleep onset latency falls by 7.06 minutes (confidence interval 4.37 to 9.75). Total sleep time increases by 8.25 minutes (1.74 to 14.75). Sleep quality improves with a standardized mean difference of 0.22.

All three results are statistically significant. They are also small. The authors say so plainly: the absolute benefit is smaller than that of other pharmacological treatments for insomnia.

One positive point, rarely mentioned: the effect does not wear off with continued use. That is a difference from several sleeping pills, and it is the reason not to set the molecule aside despite the modest gain.

Its best established effect concerns the clock, not sedation

The review published in Sleep Medicine Reviews in 2017 screened 5,030 references and kept 12, retaining only blinded randomized controlled trials. Its conclusion is more useful than that of global meta-analyses: the most convincing evidence concerns shorter sleep onset in primary insomnia, delayed sleep phase syndrome, and regulation of the sleep-wake rhythm in blind people.

What these three situations have in common is the clock, not sedation. Melatonin is a time signal. It tells the body that it is night, it does not knock it out.

A meta-analysis devoted to delayed sleep phase alone, published in Sleep in 2010, confirms this indication. In practice, this sorts requests: the person who falls asleep at 3 a.m. and wakes at 11 a.m. fits this frame. The person who wakes at 4 a.m. thinking about work does not.

The problem nobody looks at: what the capsule really contains

An analysis published in the Journal of Clinical Sleep Medicine in 2017 assayed melatonin in 31 commercial supplements by liquid chromatography. Actual content ranged from 83 percent less to 478 percent more than the declared content. From one lot to another of the same product, the gap reached 465 percent.

More than 71 percent of products did not match their label within 10 percent. And 26 percent contained serotonin, a related substance that has no place in a supplement of this kind, in amounts of 1 to 75 micrograms.

A survey of the same order was published in JAMA in 2023 on melatonin gummies sold in the United States, comparing measured amounts with declared amounts. Content variability is therefore a documented problem twice over, six years apart, in two markets and two dosage forms.

What this variability means in practice

If actual content can be five times the label, discussing dose with a client only makes sense when the product is named. Someone who says they take 1 mg may be taking 0.17 or 5.8. That explains part of the unpredictable responses, and it makes any comparison between two trials run by the same person with two brands impossible.

It also justifies a clear distinction between food supplements and the prolonged-release forms that have received a marketing authorization as a medicine. A trial in insomnia patients aged 55 to 80 documented, for one of these forms, sleep quality and next-day alertness.

The question to ask is therefore not which dose, but which product, at what time, and for how long. Timing matters more than the milligram for clock-resetting use.

Dose and duration, in light of the meta-regression

The 2013 meta-analysis tested the influence of dose and treatment duration on outcomes. Longer trials and those using higher doses show more marked effects on sleep onset latency and total sleep time.

By contrast, neither trial duration nor dose has a detectable effect on sleep quality. Raising the dose therefore does not make people sleep better, it makes them fall asleep slightly faster.

The nuance matters because the spontaneous logic of most people is to increase when it does not work. The data say the additional gain is small and concerns latency, not how people feel.

Reported effects, and the areas still unknown

A systematic review published in CNS Drugs in 2019 collected adverse events from 37 randomized trials, with doses of 0.15 to 12 mg. The most frequent are daytime drowsiness (1.66 percent), headache (0.74 percent), other sleep-related effects (0.74 percent), dizziness (0.74 percent) and hypothermia (0.62 percent).

Very few serious effects were reported. Those reported include agitation, fatigue, mood changes, nightmares, skin irritation and palpitations. Most resolved spontaneously within days or on discontinuation.

The limit lies elsewhere, and the authors state it clearly: participants were followed for up to 29 weeks, but most trials lasted 4 weeks or less. There are no robust data on continuous use over several years. That is an unknown, not demonstrated safety.

The questions to ask before discussing it

Before considering melatonin with someone, three situations must be ruled out, because they do not reflect a clock shift. Fragmented sleep with snoring and daytime drowsiness points to sleep apnea. Night awakenings with palpitations and sweating require medical advice. Insomnia established for months calls for behavioral management, whose efficacy is better established than that of any supplement.

Melatonin is also not a neutral topic in people on medication, in pregnancy, or in children. These situations fall outside the scope of a non-physician practitioner and require medical referral.

What remains is a defensible and documented use: resetting a shifted clock, in an adult without medication, with an identified product, at a fixed time, for a duration set in advance. And a calibrated expectation: a few minutes of sleep onset, not a transformed night.

Sources

  1. 1.Ferracioli-Oda E, et al. Meta-analysis: melatonin for the treatment of primary sleep disorders. PLoS One. 2013.
  2. 2.Auld F, et al. Evidence for the efficacy of melatonin in the treatment of primary adult sleep disorders. Sleep Med Rev. 2017.
  3. 3.Erland LA, Saxena PK. Melatonin Natural Health Products and Supplements: Presence of Serotonin and Significant Variability of Melatonin Content. J Clin Sleep Med. 2017.
  4. 4.Cohen PA, et al. Quantity of Melatonin and CBD in Melatonin Gummies Sold in the US. JAMA. 2023.
  5. 5.Besag FMC, et al. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review. CNS Drugs. 2019.
  6. 6.van Geijlswijk IM, et al. The use of exogenous melatonin in delayed sleep phase disorder: a meta-analysis. Sleep. 2010.
  7. 7.Wade AG, et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin. 2007.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.